Short-course rapamycin treatment enables engraftment of immunogenic gene-engineered bone marrow under low-dose irradiation to permit long-term immunological tolerance

Overview of attention for article published in Stem Cell Research & Therapy, March 2017

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (59th percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 12,064 followers.

RT @celltherapynews: Short-Course Rapamycin Treatment Enables Engraftment of Immunogenic Gene-Engineered BM @UQ_News https://t.co/7YQGC6ANDz

RT @celltherapynews: Short-Course Rapamycin Treatment Enables Engraftment of Immunogenic Gene-Engineered BM @UQ_News https://t.co/7YQGC6ANDz

RT @celltherapynews: Short-Course Rapamycin Treatment Enables Engraftment of Immunogenic Gene-Engineered BM @UQ_News https://t.co/7YQGC6ANDz

Short-Course Rapamycin Treatment Enables Engraftment of Immunogenic Gene-Engineered BM @UQ_News https://t.co/7YQGC6ANDz

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.